| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | — |
| R&D Expense | $285K | — | -28.2% |
| SG&A Expense | $789K | — | +25.1% |
| Operating Income | -$2.3M | — | -30.7% |
| Pre-tax Income | -$2.3M | — | -30.2% |
| Income Tax | $0 | — | — |
| Net Income | -$2.3M | — | -30.2% |
| EPS (Basic) | -$5.09 | — | -31.9% |
| EPS (Diluted) | -$5.09 | — | -31.9% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $1.4M | -55.7% | -16.4% |
| Accounts Receivable | $96 | -70.1% | -92.6% |
| Current Assets | $1.5M | -54.0% | -15.0% |
| Total Assets | $3.5M | -32.7% | -14.1% |
| Current Liabilities | $659K | -30.9% | +68.1% |
| Total Liabilities | $662K |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$2.3M | — | -57.6% |
| Investing Cash Flow | -$308K | — | -24.7% |
| Financing Cash Flow | $809K | — | +20.1% |
| +51.6% |
| Stockholders' Equity | $2.8M | -33.0% | -22.0% |